A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-02

AUTHORS

P S Hall, S R Lord, M Collinson, H Marshall, M Jones, C Lowe, H Howard, D Swinson, G Velikova, A Anthoney, R Roy, J Dent, S Cheeseman, K Last, M T Seymour

ABSTRACT

BACKGROUND: Elderly patients are commonly under-represented in cancer clinical trials. The 321GO was undertaken in preparation for a definitive phase three trial assessing different chemotherapy regimens in a frail and/or elderly population with advanced gastroesophageal (GO) cancer. METHODS: Patients with advanced GO cancer considered unfit for conventional dose chemotherapy were randomly assigned in a 1 : 1 : 1 ratio to: epirubicin, oxaliplatin and capecitabine (EOX); oxaliplatin and capecitabine (OX); and capecitabine alone (X) (all 80% of full dose and unblinded). The primary end point was patient recruitment over an 18-month period. A registration study recorded treatment choice for all patients with advanced GO cancer at trial centres. RESULTS: A total of 313 patients were considered for palliative chemotherapy for GO cancer over the 18-month period: 115 received full dose treatment, 89 less than standard treatment or entered 321GO and 111 no treatment. Within 321GO, 55 patients were randomly assigned (19 to OX and X; 17 to EOX). Progression-free survival (PFS) for all patients was 4.4 months and by arm 5.4, 5.6 and 3.0 months for EOX, OX and X, respectively. The number of patients with a good overall treatment utility (OTU), a novel patient-centred endpoint, at 12 weeks was 3 (18%), 6 (32%) and 1 (6%) for EOX, OX and X, respectively. At 6 weeks, 22 patients (41%) had experienced a non-haematologic toxicity ⩾grade 3, most commonly lethargy or diarrhoea. The OTU was prognostic for overall survival in patients alive at week 12 (logrank test P=0.0001). CONCLUSIONS: It is feasible to recruit elderly and/or frail patients with advanced GO cancer to a randomised clinical trial. The OX is the preferred regimen for further study. Overall treatment utility shows promise as a comparator between treatment regimens for feasibility and randomised trials in the elderly and/or frail GO cancer population. More... »

PAGES

472

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/bjc.2016.442

DOI

http://dx.doi.org/10.1038/bjc.2016.442

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1006169380

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28095397


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adenocarcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Capecitabine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Epirubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Esophageal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Feasibility Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Frail Elderly", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Organoplatinum Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Palliative Care", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Edinburgh", 
          "id": "https://www.grid.ac/institutes/grid.4305.2", 
          "name": [
            "Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh EH4 2XR, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hall", 
        "givenName": "P S", 
        "id": "sg:person.01232272557.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232272557.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Oxford", 
          "id": "https://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Department of Oncology, University of Oxford, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lord", 
        "givenName": "S R", 
        "id": "sg:person.01133307242.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133307242.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Leeds", 
          "id": "https://www.grid.ac/institutes/grid.9909.9", 
          "name": [
            "Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Collinson", 
        "givenName": "M", 
        "id": "sg:person.01335632056.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335632056.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Leeds", 
          "id": "https://www.grid.ac/institutes/grid.9909.9", 
          "name": [
            "Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marshall", 
        "givenName": "H", 
        "id": "sg:person.0624165205.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624165205.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Leeds", 
          "id": "https://www.grid.ac/institutes/grid.9909.9", 
          "name": [
            "Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jones", 
        "givenName": "M", 
        "id": "sg:person.01066234003.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066234003.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "NIHR Cancer Research Network Coordinating Centre, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lowe", 
        "givenName": "C", 
        "id": "sg:person.015377533065.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015377533065.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Leeds", 
          "id": "https://www.grid.ac/institutes/grid.9909.9", 
          "name": [
            "Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Howard", 
        "givenName": "H", 
        "id": "sg:person.01347571305.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01347571305.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Leeds", 
          "id": "https://www.grid.ac/institutes/grid.9909.9", 
          "name": [
            "Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Swinson", 
        "givenName": "D", 
        "id": "sg:person.01053344053.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053344053.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Leeds", 
          "id": "https://www.grid.ac/institutes/grid.9909.9", 
          "name": [
            "Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Velikova", 
        "givenName": "G", 
        "id": "sg:person.01145521343.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145521343.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Leeds", 
          "id": "https://www.grid.ac/institutes/grid.9909.9", 
          "name": [
            "Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Anthoney", 
        "givenName": "A", 
        "id": "sg:person.0727202416.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0727202416.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Castle Hill Hospital", 
          "id": "https://www.grid.ac/institutes/grid.413509.a", 
          "name": [
            "Department of Oncology, Castle Hill Hospital, Hull, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Roy", 
        "givenName": "R", 
        "id": "sg:person.01123510370.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123510370.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Huddersfield Royal Infirmary", 
          "id": "https://www.grid.ac/institutes/grid.417789.4", 
          "name": [
            "Department of Oncology, Huddersfield Royal Infirmary, Huddersfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dent", 
        "givenName": "J", 
        "id": "sg:person.010144257115.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010144257115.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "York Hospital", 
          "id": "https://www.grid.ac/institutes/grid.417375.3", 
          "name": [
            "Department of Oncology, The York Hospital, York, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cheeseman", 
        "givenName": "S", 
        "id": "sg:person.010741637515.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010741637515.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bradford Royal Infirmary", 
          "id": "https://www.grid.ac/institutes/grid.418447.a", 
          "name": [
            "Department of Oncology, The York Hospital, York, UK", 
            "Department of Oncology, Bradford Royal Infirmary, Bradford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Last", 
        "givenName": "K", 
        "id": "sg:person.01011236506.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01011236506.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "NIHR Cancer Research Network Coordinating Centre, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Seymour", 
        "givenName": "M T", 
        "id": "sg:person.010065613017.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010065613017.91"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.ejca.2005.08.044", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000834573"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(19950101)75:1<11::aid-cncr2820750104>3.0.co;2-n", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011077422"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa010957", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012569804"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa073149", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014019609"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.54.1011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014148840"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0021-9681(87)90171-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020988115"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2007.07.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023202393"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf03339847", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025692851", 
          "https://doi.org/10.1007/bf03339847"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2288-10-67", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026717986", 
          "https://doi.org/10.1186/1471-2288-10-67"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(13)70096-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043828548"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(11)60399-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047680687"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmc0911925", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049858409"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/85.5.365", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059818446"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/026921558700100409", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063799271"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/026921558700100409", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063799271"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.8.2412", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074549860"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078314942", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083143992", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-02", 
    "datePublishedReg": "2017-02-01", 
    "description": "BACKGROUND: Elderly patients are commonly under-represented in cancer clinical trials. The 321GO was undertaken in preparation for a definitive phase three trial assessing different chemotherapy regimens in a frail and/or elderly population with advanced gastroesophageal (GO) cancer.\nMETHODS: Patients with advanced GO cancer considered unfit for conventional dose chemotherapy were randomly assigned in a 1\u2009:\u20091\u2009:\u20091 ratio to: epirubicin, oxaliplatin and capecitabine (EOX); oxaliplatin and capecitabine (OX); and capecitabine alone (X) (all 80% of full dose and unblinded). The primary end point was patient recruitment over an 18-month period. A registration study recorded treatment choice for all patients with advanced GO cancer at trial centres.\nRESULTS: A total of 313 patients were considered for palliative chemotherapy for GO cancer over the 18-month period: 115 received full dose treatment, 89 less than standard treatment or entered 321GO and 111 no treatment. Within 321GO, 55 patients were randomly assigned (19 to OX and X; 17 to EOX). Progression-free survival (PFS) for all patients was 4.4 months and by arm 5.4, 5.6 and 3.0 months for EOX, OX and X, respectively. The number of patients with a good overall treatment utility (OTU), a novel patient-centred endpoint, at 12 weeks was 3 (18%), 6 (32%) and 1 (6%) for EOX, OX and X, respectively. At 6 weeks, 22 patients (41%) had experienced a non-haematologic toxicity \u2a7egrade 3, most commonly lethargy or diarrhoea. The OTU was prognostic for overall survival in patients alive at week 12 (logrank test P=0.0001).\nCONCLUSIONS: It is feasible to recruit elderly and/or frail patients with advanced GO cancer to a randomised clinical trial. The OX is the preferred regimen for further study. Overall treatment utility shows promise as a comparator between treatment regimens for feasibility and randomised trials in the elderly and/or frail GO cancer population.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/bjc.2016.442", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "116"
      }
    ], 
    "name": "A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO)", 
    "pagination": "472", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "1d63548314addba9a93ea63c379c13240be5d622903c58591270a297b44628d4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28095397"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0370635"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/bjc.2016.442"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1006169380"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/bjc.2016.442", 
      "https://app.dimensions.ai/details/publication/pub.1006169380"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T00:03", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8695_00000421.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://www.nature.com/articles/bjc2016442"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/bjc.2016.442'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/bjc.2016.442'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/bjc.2016.442'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/bjc.2016.442'


 

This table displays all metadata directly associated to this object as RDF triples.

310 TRIPLES      21 PREDICATES      63 URIs      38 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/bjc.2016.442 schema:about N101484913fc04ce5bf19f995d98d107b
2 N1c367cc60d104295a8cc12708996cabf
3 N1da074da3c6144d0b74de58270b1b62f
4 N383879c080a24b9da875009e3d65ca1f
5 N410a5707cdfa40caad65fbe9139dc653
6 N4f4174709de842f68d93fe603681e87c
7 N5e7c4a0661c24ce490005b132e01708d
8 N62852cd4387c4bea9578ab55ae873f26
9 N67e27e61a18542efbdac5d1083236267
10 N94dbb991bdbc4b2abe7a7b7198977341
11 N97e32ca152394148b5eb9ee19275ee3e
12 N987956c6cbe3452a8e26c82710a75ba0
13 N9c2a0658376647cfac320295b27bca3b
14 Nb1d49d2d63e54af9b9472ae6c63d7253
15 Nb4dd3e97ced94a8097e16223d74f9d63
16 Neeefeee06dd14e639cf6f9ee0e798e0d
17 Nfc39ed1c711c4cf6aac0bccba396cd4d
18 anzsrc-for:11
19 anzsrc-for:1112
20 schema:author N9fb58b2581d14796be0254f0979ab5b4
21 schema:citation sg:pub.10.1007/bf03339847
22 sg:pub.10.1186/1471-2288-10-67
23 https://app.dimensions.ai/details/publication/pub.1078314942
24 https://app.dimensions.ai/details/publication/pub.1083143992
25 https://doi.org/10.1002/1097-0142(19950101)75:1<11::aid-cncr2820750104>3.0.co;2-n
26 https://doi.org/10.1016/0021-9681(87)90171-8
27 https://doi.org/10.1016/j.ejca.2005.08.044
28 https://doi.org/10.1016/j.ejca.2007.07.005
29 https://doi.org/10.1016/s0140-6736(11)60399-1
30 https://doi.org/10.1016/s1470-2045(13)70096-2
31 https://doi.org/10.1056/nejmc0911925
32 https://doi.org/10.1056/nejmoa010957
33 https://doi.org/10.1056/nejmoa073149
34 https://doi.org/10.1093/jnci/85.5.365
35 https://doi.org/10.1177/026921558700100409
36 https://doi.org/10.1200/jco.1999.17.8.2412
37 https://doi.org/10.1200/jco.2013.54.1011
38 schema:datePublished 2017-02
39 schema:datePublishedReg 2017-02-01
40 schema:description BACKGROUND: Elderly patients are commonly under-represented in cancer clinical trials. The 321GO was undertaken in preparation for a definitive phase three trial assessing different chemotherapy regimens in a frail and/or elderly population with advanced gastroesophageal (GO) cancer. METHODS: Patients with advanced GO cancer considered unfit for conventional dose chemotherapy were randomly assigned in a 1 : 1 : 1 ratio to: epirubicin, oxaliplatin and capecitabine (EOX); oxaliplatin and capecitabine (OX); and capecitabine alone (X) (all 80% of full dose and unblinded). The primary end point was patient recruitment over an 18-month period. A registration study recorded treatment choice for all patients with advanced GO cancer at trial centres. RESULTS: A total of 313 patients were considered for palliative chemotherapy for GO cancer over the 18-month period: 115 received full dose treatment, 89 less than standard treatment or entered 321GO and 111 no treatment. Within 321GO, 55 patients were randomly assigned (19 to OX and X; 17 to EOX). Progression-free survival (PFS) for all patients was 4.4 months and by arm 5.4, 5.6 and 3.0 months for EOX, OX and X, respectively. The number of patients with a good overall treatment utility (OTU), a novel patient-centred endpoint, at 12 weeks was 3 (18%), 6 (32%) and 1 (6%) for EOX, OX and X, respectively. At 6 weeks, 22 patients (41%) had experienced a non-haematologic toxicity ⩾grade 3, most commonly lethargy or diarrhoea. The OTU was prognostic for overall survival in patients alive at week 12 (logrank test P=0.0001). CONCLUSIONS: It is feasible to recruit elderly and/or frail patients with advanced GO cancer to a randomised clinical trial. The OX is the preferred regimen for further study. Overall treatment utility shows promise as a comparator between treatment regimens for feasibility and randomised trials in the elderly and/or frail GO cancer population.
41 schema:genre research_article
42 schema:inLanguage en
43 schema:isAccessibleForFree true
44 schema:isPartOf N1943179783fc49ff92477759d4620680
45 Ndc1198347a724ec8a36f9c27a2a75771
46 sg:journal.1017082
47 schema:name A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO)
48 schema:pagination 472
49 schema:productId N01a68abed67a4fbc861b96740c0f45c1
50 N0a5a0df1d3db4b5695699a764dccc2ce
51 N1eac5b9bdf9940b69bbe24d884c46d41
52 N7d4be69b29734caebf867264e7ce141b
53 Ndf48d7b95d55406593c1ff85abc55c5f
54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006169380
55 https://doi.org/10.1038/bjc.2016.442
56 schema:sdDatePublished 2019-04-11T00:03
57 schema:sdLicense https://scigraph.springernature.com/explorer/license/
58 schema:sdPublisher N3622b8b27dd14ed698ff82772c29dabd
59 schema:url https://www.nature.com/articles/bjc2016442
60 sgo:license sg:explorer/license/
61 sgo:sdDataset articles
62 rdf:type schema:ScholarlyArticle
63 N01a68abed67a4fbc861b96740c0f45c1 schema:name nlm_unique_id
64 schema:value 0370635
65 rdf:type schema:PropertyValue
66 N0a5a0df1d3db4b5695699a764dccc2ce schema:name dimensions_id
67 schema:value pub.1006169380
68 rdf:type schema:PropertyValue
69 N0c2846e4ef6748b0a80af473d5dbec87 rdf:first sg:person.010144257115.34
70 rdf:rest N5061999d2e4a4417aa1702af0034d084
71 N101484913fc04ce5bf19f995d98d107b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Male
73 rdf:type schema:DefinedTerm
74 N15ea5c8e972e47198b2c91fcca3ba937 rdf:first sg:person.01145521343.84
75 rdf:rest N3afa4f07661f4710862b43e4c5c4166d
76 N1943179783fc49ff92477759d4620680 schema:volumeNumber 116
77 rdf:type schema:PublicationVolume
78 N1affdbc565c0437dad002240d9c6c2b3 rdf:first sg:person.01011236506.59
79 rdf:rest N479e89ae912f43969cf6bc7e9d199649
80 N1c367cc60d104295a8cc12708996cabf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Adenocarcinoma
82 rdf:type schema:DefinedTerm
83 N1da074da3c6144d0b74de58270b1b62f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Capecitabine
85 rdf:type schema:DefinedTerm
86 N1eac5b9bdf9940b69bbe24d884c46d41 schema:name readcube_id
87 schema:value 1d63548314addba9a93ea63c379c13240be5d622903c58591270a297b44628d4
88 rdf:type schema:PropertyValue
89 N25925efab53144f19b6f10a410f00b9d schema:name NIHR Cancer Research Network Coordinating Centre, Leeds, UK
90 rdf:type schema:Organization
91 N3622b8b27dd14ed698ff82772c29dabd schema:name Springer Nature - SN SciGraph project
92 rdf:type schema:Organization
93 N383879c080a24b9da875009e3d65ca1f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Palliative Care
95 rdf:type schema:DefinedTerm
96 N3afa4f07661f4710862b43e4c5c4166d rdf:first sg:person.0727202416.01
97 rdf:rest Nb1a51dd4b0904c8885560a902edc2b81
98 N410a5707cdfa40caad65fbe9139dc653 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Fluorouracil
100 rdf:type schema:DefinedTerm
101 N479e89ae912f43969cf6bc7e9d199649 rdf:first sg:person.010065613017.91
102 rdf:rest rdf:nil
103 N4d186ffce1bd4fdabcede2f6f5cf8d79 rdf:first sg:person.0624165205.08
104 rdf:rest N5820202b27c144948d808bb4896088c3
105 N4f4174709de842f68d93fe603681e87c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Epirubicin
107 rdf:type schema:DefinedTerm
108 N5061999d2e4a4417aa1702af0034d084 rdf:first sg:person.010741637515.42
109 rdf:rest N1affdbc565c0437dad002240d9c6c2b3
110 N5820202b27c144948d808bb4896088c3 rdf:first sg:person.01066234003.22
111 rdf:rest Nbb588472d07e48c4887e854ee0af36bf
112 N5e7c4a0661c24ce490005b132e01708d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Deoxycytidine
114 rdf:type schema:DefinedTerm
115 N62852cd4387c4bea9578ab55ae873f26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Organoplatinum Compounds
117 rdf:type schema:DefinedTerm
118 N677b514ee3af415d8ec08aeeb9069f58 schema:name NIHR Cancer Research Network Coordinating Centre, Leeds, UK
119 rdf:type schema:Organization
120 N67e27e61a18542efbdac5d1083236267 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Esophageal Neoplasms
122 rdf:type schema:DefinedTerm
123 N7a1e780c9b4943cea169f6799192d17c rdf:first sg:person.01053344053.92
124 rdf:rest N15ea5c8e972e47198b2c91fcca3ba937
125 N7b3e07f013184d409c88970fc302b4bb rdf:first sg:person.01133307242.30
126 rdf:rest Na5fceba337304c12845ff5f7e870c7ba
127 N7d4be69b29734caebf867264e7ce141b schema:name pubmed_id
128 schema:value 28095397
129 rdf:type schema:PropertyValue
130 N89cc785759be48b08b61ea6320e1e108 rdf:first sg:person.01347571305.92
131 rdf:rest N7a1e780c9b4943cea169f6799192d17c
132 N94dbb991bdbc4b2abe7a7b7198977341 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Antineoplastic Combined Chemotherapy Protocols
134 rdf:type schema:DefinedTerm
135 N97e32ca152394148b5eb9ee19275ee3e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Disease Progression
137 rdf:type schema:DefinedTerm
138 N987956c6cbe3452a8e26c82710a75ba0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Humans
140 rdf:type schema:DefinedTerm
141 N9c2a0658376647cfac320295b27bca3b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Frail Elderly
143 rdf:type schema:DefinedTerm
144 N9fb58b2581d14796be0254f0979ab5b4 rdf:first sg:person.01232272557.00
145 rdf:rest N7b3e07f013184d409c88970fc302b4bb
146 Na5fceba337304c12845ff5f7e870c7ba rdf:first sg:person.01335632056.21
147 rdf:rest N4d186ffce1bd4fdabcede2f6f5cf8d79
148 Nb1a51dd4b0904c8885560a902edc2b81 rdf:first sg:person.01123510370.80
149 rdf:rest N0c2846e4ef6748b0a80af473d5dbec87
150 Nb1d49d2d63e54af9b9472ae6c63d7253 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Feasibility Studies
152 rdf:type schema:DefinedTerm
153 Nb4dd3e97ced94a8097e16223d74f9d63 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Female
155 rdf:type schema:DefinedTerm
156 Nbb588472d07e48c4887e854ee0af36bf rdf:first sg:person.015377533065.48
157 rdf:rest N89cc785759be48b08b61ea6320e1e108
158 Ndc1198347a724ec8a36f9c27a2a75771 schema:issueNumber 4
159 rdf:type schema:PublicationIssue
160 Ndf48d7b95d55406593c1ff85abc55c5f schema:name doi
161 schema:value 10.1038/bjc.2016.442
162 rdf:type schema:PropertyValue
163 Neeefeee06dd14e639cf6f9ee0e798e0d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Aged
165 rdf:type schema:DefinedTerm
166 Nfc39ed1c711c4cf6aac0bccba396cd4d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Aged, 80 and over
168 rdf:type schema:DefinedTerm
169 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
170 schema:name Medical and Health Sciences
171 rdf:type schema:DefinedTerm
172 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
173 schema:name Oncology and Carcinogenesis
174 rdf:type schema:DefinedTerm
175 sg:journal.1017082 schema:issn 0007-0920
176 1532-1827
177 schema:name British Journal of Cancer
178 rdf:type schema:Periodical
179 sg:person.010065613017.91 schema:affiliation N677b514ee3af415d8ec08aeeb9069f58
180 schema:familyName Seymour
181 schema:givenName M T
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010065613017.91
183 rdf:type schema:Person
184 sg:person.01011236506.59 schema:affiliation https://www.grid.ac/institutes/grid.418447.a
185 schema:familyName Last
186 schema:givenName K
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01011236506.59
188 rdf:type schema:Person
189 sg:person.010144257115.34 schema:affiliation https://www.grid.ac/institutes/grid.417789.4
190 schema:familyName Dent
191 schema:givenName J
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010144257115.34
193 rdf:type schema:Person
194 sg:person.01053344053.92 schema:affiliation https://www.grid.ac/institutes/grid.9909.9
195 schema:familyName Swinson
196 schema:givenName D
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053344053.92
198 rdf:type schema:Person
199 sg:person.01066234003.22 schema:affiliation https://www.grid.ac/institutes/grid.9909.9
200 schema:familyName Jones
201 schema:givenName M
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066234003.22
203 rdf:type schema:Person
204 sg:person.010741637515.42 schema:affiliation https://www.grid.ac/institutes/grid.417375.3
205 schema:familyName Cheeseman
206 schema:givenName S
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010741637515.42
208 rdf:type schema:Person
209 sg:person.01123510370.80 schema:affiliation https://www.grid.ac/institutes/grid.413509.a
210 schema:familyName Roy
211 schema:givenName R
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123510370.80
213 rdf:type schema:Person
214 sg:person.01133307242.30 schema:affiliation https://www.grid.ac/institutes/grid.4991.5
215 schema:familyName Lord
216 schema:givenName S R
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133307242.30
218 rdf:type schema:Person
219 sg:person.01145521343.84 schema:affiliation https://www.grid.ac/institutes/grid.9909.9
220 schema:familyName Velikova
221 schema:givenName G
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145521343.84
223 rdf:type schema:Person
224 sg:person.01232272557.00 schema:affiliation https://www.grid.ac/institutes/grid.4305.2
225 schema:familyName Hall
226 schema:givenName P S
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232272557.00
228 rdf:type schema:Person
229 sg:person.01335632056.21 schema:affiliation https://www.grid.ac/institutes/grid.9909.9
230 schema:familyName Collinson
231 schema:givenName M
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335632056.21
233 rdf:type schema:Person
234 sg:person.01347571305.92 schema:affiliation https://www.grid.ac/institutes/grid.9909.9
235 schema:familyName Howard
236 schema:givenName H
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01347571305.92
238 rdf:type schema:Person
239 sg:person.015377533065.48 schema:affiliation N25925efab53144f19b6f10a410f00b9d
240 schema:familyName Lowe
241 schema:givenName C
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015377533065.48
243 rdf:type schema:Person
244 sg:person.0624165205.08 schema:affiliation https://www.grid.ac/institutes/grid.9909.9
245 schema:familyName Marshall
246 schema:givenName H
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624165205.08
248 rdf:type schema:Person
249 sg:person.0727202416.01 schema:affiliation https://www.grid.ac/institutes/grid.9909.9
250 schema:familyName Anthoney
251 schema:givenName A
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0727202416.01
253 rdf:type schema:Person
254 sg:pub.10.1007/bf03339847 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025692851
255 https://doi.org/10.1007/bf03339847
256 rdf:type schema:CreativeWork
257 sg:pub.10.1186/1471-2288-10-67 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026717986
258 https://doi.org/10.1186/1471-2288-10-67
259 rdf:type schema:CreativeWork
260 https://app.dimensions.ai/details/publication/pub.1078314942 schema:CreativeWork
261 https://app.dimensions.ai/details/publication/pub.1083143992 schema:CreativeWork
262 https://doi.org/10.1002/1097-0142(19950101)75:1<11::aid-cncr2820750104>3.0.co;2-n schema:sameAs https://app.dimensions.ai/details/publication/pub.1011077422
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1016/0021-9681(87)90171-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020988115
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1016/j.ejca.2005.08.044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000834573
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1016/j.ejca.2007.07.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023202393
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1016/s0140-6736(11)60399-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047680687
271 rdf:type schema:CreativeWork
272 https://doi.org/10.1016/s1470-2045(13)70096-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043828548
273 rdf:type schema:CreativeWork
274 https://doi.org/10.1056/nejmc0911925 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049858409
275 rdf:type schema:CreativeWork
276 https://doi.org/10.1056/nejmoa010957 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012569804
277 rdf:type schema:CreativeWork
278 https://doi.org/10.1056/nejmoa073149 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014019609
279 rdf:type schema:CreativeWork
280 https://doi.org/10.1093/jnci/85.5.365 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059818446
281 rdf:type schema:CreativeWork
282 https://doi.org/10.1177/026921558700100409 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063799271
283 rdf:type schema:CreativeWork
284 https://doi.org/10.1200/jco.1999.17.8.2412 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074549860
285 rdf:type schema:CreativeWork
286 https://doi.org/10.1200/jco.2013.54.1011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014148840
287 rdf:type schema:CreativeWork
288 https://www.grid.ac/institutes/grid.413509.a schema:alternateName Castle Hill Hospital
289 schema:name Department of Oncology, Castle Hill Hospital, Hull, UK
290 rdf:type schema:Organization
291 https://www.grid.ac/institutes/grid.417375.3 schema:alternateName York Hospital
292 schema:name Department of Oncology, The York Hospital, York, UK
293 rdf:type schema:Organization
294 https://www.grid.ac/institutes/grid.417789.4 schema:alternateName Huddersfield Royal Infirmary
295 schema:name Department of Oncology, Huddersfield Royal Infirmary, Huddersfield, UK
296 rdf:type schema:Organization
297 https://www.grid.ac/institutes/grid.418447.a schema:alternateName Bradford Royal Infirmary
298 schema:name Department of Oncology, Bradford Royal Infirmary, Bradford, UK
299 Department of Oncology, The York Hospital, York, UK
300 rdf:type schema:Organization
301 https://www.grid.ac/institutes/grid.4305.2 schema:alternateName University of Edinburgh
302 schema:name Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh EH4 2XR, UK
303 rdf:type schema:Organization
304 https://www.grid.ac/institutes/grid.4991.5 schema:alternateName University of Oxford
305 schema:name Department of Oncology, University of Oxford, Oxford, UK
306 rdf:type schema:Organization
307 https://www.grid.ac/institutes/grid.9909.9 schema:alternateName University of Leeds
308 schema:name Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
309 Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
310 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...